MELBOURNE – Global Kinetics has received clearance from the U.S. Food and Drug Administration for its Personal KinetiGraph, a device designed to improve the assessment and monitoring of Parkinson’s disease and other neurological disorders that affect movement. “This technology brings clinicians a whole new level of accurate information to support more effective and timely treatment decisions,” said Malcolm Horne, Ph.D., Global Kinetics co-founder, in a press release. The Personal KinetiGraph is a wrist-worn device that automatically records motion data over a period of up to 10 days. Clinicians receive detailed information about a patient’s mobility, identifying changes and trends that could help in the diagnosis and treatment of Parkinson’s. The device can also remind patients to take medication and track when it is taken to help with adherence. “The Personal KinetiGraph provides clinicians with a clear and accurate assessment of the patient experience outside of office visits and examinations,” said Andrew Maxwell, Global Kinetics managing director and CEO, in a statement.
You are here: / / Global Kinetics’ KinetiGraph gets FDA clearance